Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy with Camrelizumab and Apatinib for VP4 Liver Cancer
NCT06632522Phase 2Not yet recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Oct 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoint: Overall Survival at 3 years. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06632522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632522.